Lil­ly bests No­vo Nordisk in ob­ser­va­tion­al study of GLP-1 drugs

Pa­tients re­ceiv­ing Eli Lil­ly’s di­a­betes med­i­cine Moun­jaro were “sig­nif­i­cant­ly more like­ly” to achieve clin­i­cal­ly mean­ing­ful weight loss com­pared to those on No­vo Nordisk’s Ozem­pic, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.